0001140361-23-011300.txt : 20230313 0001140361-23-011300.hdr.sgml : 20230313 20230313084522 ACCESSION NUMBER: 0001140361-23-011300 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230313 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230313 DATE AS OF CHANGE: 20230313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDS Biotechnology Corp CENTRAL INDEX KEY: 0001472091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 264231384 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37568 FILM NUMBER: 23725851 BUSINESS ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 800-208-3343 MAIL ADDRESS: STREET 1: 25B VREELAND ROAD STREET 2: SUITE 300 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: Edge Therapeutics, Inc. DATE OF NAME CHANGE: 20090911 8-K 1 brhc10049614_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 
FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 13, 2023

 
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-37568
26-4231384
     
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
25B Vreeland Road
25B Vreeland Road, Suite 300, Florham Park, NJ 07932
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

  ☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  ☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  ☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 7.01.
Regulation FD Disclosure.

PDS Biotechnology Corporation (the “Company”) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”) and appointment of the Federal Deposit Insurance Corporation as receiver. The Company does not hold any cash or securities at SVB and it does not have any banking relationship with SVB.  Therefore, the Company believes it does not have exposure to any liquidity concerns at SVB.

The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 9.01
Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
Number
  
Description
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL Document)
 
Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
   
Date: March 13, 2023
By:
/s/ Frank Bedu-Addo, Ph.D.
 
Name:
Frank Bedu-Addo, Ph.D.
 
Title
: President and Chief Executive Officer


EX-101.SCH 2 pdsb-20230313.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 pdsb-20230313_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 4 pdsb-20230313_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Mar. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 13, 2023
Entity File Number 001-37568
Entity Registrant Name PDS BIOTECHNOLOGY CORPORATION
Entity Central Index Key 0001472091
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-4231384
Entity Address, Address Line One 25B Vreeland Road
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code 800
Local Phone Number 208-3343
Title of 12(b) Security Common Stock, par value $0.00033 per share
Trading Symbol PDSB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 6 brhc10049614_8k_htm.xml IDEA: XBRL DOCUMENT 0001472091 2023-03-13 2023-03-13 false 0001472091 NASDAQ 8-K 2023-03-13 PDS BIOTECHNOLOGY CORPORATION DE 001-37568 26-4231384 25B Vreeland Road 25B Vreeland Road Suite 300 Florham Park NJ 07932 800 208-3343 false false false false Common Stock, par value $0.00033 per share PDSB false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://pdsbiotech.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - brhc10049614_8k.htm 11 brhc10049614_8k.htm pdsb-20230313.xsd pdsb-20230313_lab.xml pdsb-20230313_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10049614_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10049614_8k.htm" ] }, "labelLink": { "local": [ "pdsb-20230313_lab.xml" ] }, "presentationLink": { "local": [ "pdsb-20230313_pre.xml" ] }, "schema": { "local": [ "pdsb-20230313.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "pdsb", "nsuri": "http://pdsbiotech.com/20230313", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10049614_8k.htm", "contextRef": "c20230313to20230313", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://pdsbiotech.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10049614_8k.htm", "contextRef": "c20230313to20230313", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "trueItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://pdsbiotech.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001140361-23-011300-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-011300-xbrl.zip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